RTW Investments LP Invests $15.90 Million in SAGE Therapeutics Inc (SAGE)

RTW Investments LP bought a new stake in SAGE Therapeutics Inc (NASDAQ:SAGE) during the 4th quarter, HoldingsChannel reports. The fund bought 165,990 shares of the biopharmaceutical company’s stock, valued at approximately $15,900,000. SAGE Therapeutics comprises 1.5% of RTW Investments LP’s portfolio, making the stock its 20th largest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Virtus ETF Advisers LLC increased its position in shares of SAGE Therapeutics by 2.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,948 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 77 shares during the period. Daiwa Securities Group Inc. increased its position in shares of SAGE Therapeutics by 34.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 80 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of SAGE Therapeutics by 2.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,676 shares of the biopharmaceutical company’s stock valued at $831,000 after acquiring an additional 239 shares during the period. Principal Financial Group Inc. increased its position in shares of SAGE Therapeutics by 1.1% in the 4th quarter. Principal Financial Group Inc. now owns 23,202 shares of the biopharmaceutical company’s stock valued at $2,222,000 after acquiring an additional 243 shares during the period. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in shares of SAGE Therapeutics in the 4th quarter valued at $29,000.

NASDAQ:SAGE traded down $0.27 during mid-day trading on Monday, hitting $156.72. The company’s stock had a trading volume of 6,563 shares, compared to its average volume of 596,052. SAGE Therapeutics Inc has a 1 year low of $79.88 and a 1 year high of $188.82. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of -19.18 and a beta of 2.92.



SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) EPS for the quarter, missing the consensus estimate of ($2.89) by ($0.49). The business had revenue of $0.27 million for the quarter. During the same period last year, the business earned ($1.75) EPS. On average, research analysts predict that SAGE Therapeutics Inc will post -12.47 EPS for the current year.

In other news, Director James M. Frates sold 7,500 shares of the stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $134.81, for a total transaction of $1,011,075.00. Following the sale, the director now directly owns 11,735 shares of the company’s stock, valued at approximately $1,581,995.35. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Steven M. Paul sold 49,461 shares of the stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $161.02, for a total transaction of $7,964,210.22. Following the sale, the director now directly owns 272,777 shares in the company, valued at $43,922,552.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 175,811 shares of company stock worth $27,771,729. 5.10% of the stock is owned by corporate insiders.

SAGE has been the topic of several research reports. BidaskClub downgraded SAGE Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 30th. Guggenheim initiated coverage on SAGE Therapeutics in a research report on Friday, February 22nd. They issued a “buy” rating and a $205.00 target price on the stock. Wolfe Research initiated coverage on SAGE Therapeutics in a research report on Friday, December 14th. They issued an “outperform” rating on the stock. ValuEngine downgraded SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Finally, Morgan Stanley lowered their price target on shares of SAGE Therapeutics from $230.00 to $213.00 and set an “overweight” rating on the stock in a report on Wednesday, December 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $201.45.

ILLEGAL ACTIVITY WARNING: “RTW Investments LP Invests $15.90 Million in SAGE Therapeutics Inc (SAGE)” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://dakotafinancialnews.com/2019/03/25/rtw-investments-lp-invests-15-90-million-in-sage-therapeutics-inc-sage.html.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.